Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Sarah Halford"'
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Modern cancer therapeutics are increasingly targeted, bringing the promise of new and improved activity, alongside better tolerability. However, while many are indeed resulting in dramatic improvements in disease control and patient survival, short-
Externí odkaz:
https://doaj.org/article/0bbf4a7b3d594c28a1a9ebc08cffbed6
Autor:
Sarah Halford, Susan Wan, Ilaria Dragoni, Julie Silvester, Bobojon Nazarov, Daniel Anthony, Suzie Anthony, Emma Ladds, John Norrie, Kevin Dhaliwal, the CDD SPIKE-1 Project Team
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-3 (2021)
Abstract Objectives The primary objective is to evaluate the efficacy of camostat to prevent respiratory deterioration in patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Secondary objectives include assessment of
Externí odkaz:
https://doaj.org/article/e31a8454fa154c06ae0d8991f49959f8
Autor:
Sarah Halford, Susan Wan, Ilaria Dragoni, Julie Silvester, Bobojon Nazarov, Daniel Anthony, Suzie Anthony, Emma Ladds, John Norrie, Kevin Dhaliwal, and the CDD SPIKE-1 Project Team
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/b21f19e815dd45c1a5e94555ef323a1a
Autor:
Sarah Halford, Gareth J. Veal, Stephen R. Wedge, Geoffrey S. Payne, Chris M. Bacon, Philip Sloan, Ilaria Dragoni, Kathrin Heinzmann, Sarah Potter, Becky M. Salisbury, Maxime Chénard-Poirier, Alastair Greystoke, Elizabeth C. Howell, William A. Innes, Karen Morris, Chris Plummer, Mihaela Rata, George Petrides, Hector C. Keun, Udai Banerji, Ruth Plummer
Publikováno v:
Clin Cancer Res
Purpose: Inhibition of monocarboxylate transporter (MCT) 1–mediated lactate transport may have cytostatic and/or cytotoxic effects on tumor cells. We report results from the dose-escalation part of a first-in-human trial of AZD3965, a first-in-clas
Autor:
Ruth Plummer, Udai Banerji, Hector C. Keun, George Petrides, Mihaela Rata, Chris Plummer, Karen Morris, William A. Innes, Elizabeth C. Howell, Alastair Greystoke, Maxime Chénard-Poirier, Becky M. Salisbury, Sarah Potter, Kathrin Heinzmann, Ilaria Dragoni, Philip Sloan, Chris M. Bacon, Geoffrey S. Payne, Stephen R. Wedge, Gareth J. Veal, Sarah Halford
Purpose:Inhibition of monocarboxylate transporter (MCT) 1–mediated lactate transport may have cytostatic and/or cytotoxic effects on tumor cells. We report results from the dose-escalation part of a first-in-human trial of AZD3965, a first-in-class
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9da6bf5d5915d482989d62e386cae2f
https://doi.org/10.1158/1078-0432.c.6533131.v2
https://doi.org/10.1158/1078-0432.c.6533131.v2
Autor:
Ruth Plummer, Udai Banerji, Hector C. Keun, George Petrides, Mihaela Rata, Chris Plummer, Karen Morris, William A. Innes, Elizabeth C. Howell, Alastair Greystoke, Maxime Chénard-Poirier, Becky M. Salisbury, Sarah Potter, Kathrin Heinzmann, Ilaria Dragoni, Philip Sloan, Chris M. Bacon, Geoffrey S. Payne, Stephen R. Wedge, Gareth J. Veal, Sarah Halford
supplementary data: Methods, tables, figure.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3af17ae9e71a78dc3c42f946b96696d2
https://doi.org/10.1158/1078-0432.22490317
https://doi.org/10.1158/1078-0432.22490317
Autor:
Christian H. Ottensmeier, Freda K. Stevenson, Gareth J. Thomas, Ugur Sahin, Petra Simon, Toni Weinschenk, Duncan I. Jodrell, Alan Anthoney, Sally Clive, Ann O'Callaghan, Andrew Bateman, Sarah Halford, Ceri Edwards, Emily Buxton, Paul Lloyd-Evans, Andrew King, Stephen M. Thirdborough, Jana Stasakova, Lindsey Chudley, Angelica Cazaly, Ann Mander, Katy J. McCann
Purpose: We have clinically evaluated a DNA fusion vaccine to target the HLA-A*0201–binding peptide CAP-1 from carcinoembryonic antigen (CEA605–613) linked to an immunostimulatory domain (DOM) from fragment C of tetanus toxin.Experimental Design:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4202489da8884143afe28a39cda33e82
https://doi.org/10.1158/1078-0432.c.6524756.v1
https://doi.org/10.1158/1078-0432.c.6524756.v1
Autor:
Catherine Hanna, Sarah Jefferies, Marc Pittman, Kathreena M Kurian, Rebecca Sleigh, Karin Williams, Sara Erridge, Catherine McBain, Garth Cruickshank, Ross Carruthers, Colin Watts, Alan Jackson, Laurence Dunn, Lisa Godfrey, Karen Strathdee, Anthony J. Chalmers, Alex McCormick, Sarah Halford
Publikováno v:
Neuro Oncol
Background The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib potentiated radiation and temozolomide (TMZ) chemotherapy in preclinical glioblastoma models but brain penetration was poor. Clinically, PARP inhibitors exacerbate the hematological
Autor:
Kathrin Heinzmann, Gareth J. Veal, Laura Brotherton, William Townsend, Martin J. S. Dyer, Chris M. Bacon, Ilaria Dragoni, Pamela McKay, Elizabeth Ruth Plummer, Hector C. Keun, Harriet S. Walter, Kim Linton, Steve R. Wedge, Sarah Halford, Alexandros P. Siskos
Publikováno v:
Halford, S E R, Walter, H, McKay, P, Townsend, W, Linton, K, Heinzmann, K, Dragoni, I, Brotherton, L, Veal, G, Siskos, A, Keun, H C, Bacon, C, Wedge, S, Dyer, M J S & Plummer, E R 2021, ' Phase I expansion study of the first-in-class monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). ', Journal of Clinical Oncology, vol. 39, no. 15_suppl, pp. 3115-3115 . https://doi.org/10.1200/jco.2021.39.15_suppl.3115
ASCO Annual Meeting I
ASCO Annual Meeting I
3115 Background: Tumours rely on lactate transporters (MCT1-4) to maintain glycolytic flux and avoid intracellular acidification. In haematological tumours the MCT1 transporter acts as a lactate and pyruvate exporter. AZD3965 is a potent and specific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f90d8d48f356d0ee9e4a7761b45a9d92
https://doi.org/10.1200/jco.2021.39.15_suppl.3115
https://doi.org/10.1200/jco.2021.39.15_suppl.3115
Autor:
Duncan I. Jodrell, Daniel H. Palmer, Sarah Halford, J. Evans, Lisa V. Hampson, Balaji Venugopal, Robert McLeod, Mirela Hategan, Natalie Cook, Helen Turner, Donna Michelle Smith, Bristi Basu, Aarthi Gopinathan, Michael Nebozhyn, D. Alan Anthoney, David A. Tuveson, William P. Steward, David Propper, Hayley Farmer-Hall
Publikováno v:
Cook, N, Basu, B, Smith, D M, Gopinathan, A, Evans, J, Steward, W P, Palmer, D, Propper, D, Venugopal, B, Hategan, M, Anthoney, D A, Hampson, L V, Nebozhyn, M, Tuveson, D, Farmer-Hall, H, Turner, H, McLeod, R, Halford, S & Jodrell, D 2018, ' A phase i trial of the c-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma ', British Journal of Cancer, vol. 118, no. 6, pp. 793-801 . https://doi.org/10.1038/bjc.2017.495
British Journal of Cancer
British Journal of Cancer
Background: The Notch pathway is frequently activated in cancer. Pathway inhibition by g-secretase inhibitors has been shown to be effective in pre-clinical models of pancreatic cancer, in combination with gemcitabine. Methods: A multi-centre, non-ra